Project without external funding

Development of antagonists that disrupt the hyperactivated cAMP signalling pathway in immunodeficiencies as immunostimulatory therapy - New cAMP antagonists

Project Details
Project duration: 09/200308/2005

The present proposal aims to develop drugs for the immunomodulating therapy in HIV and other immunodeficiencies based on proprietary technology. This technology is based on new knowledge showing that activation of a signal pathway involving the signal substance cAMP and protein kinase A type I, PKAI, inside white blood cells, T lymphocytes, inhibits the function of the immune system. During HIV infection, the activity of this signal pathway is highly increased due to elevated levels of cAMP and the function of the patient"s white blood cells is strongly reduced. Objectives include development of new chemical entities suitable that act as antagonists of cAMP action as drugs to improve the immune function of T lymphocytes and the development of screening methods to assess such compounds. Further objectives include ex vivo clinical testing of compounds and in vivo proof-of-principle experiments in a mouse disease model, murine AIDS.

Last updated on 2017-11-07 at 14:36

Share link